GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00140208 | Oral cavity | OSCC | primary neural tube formation | 55/7305 | 94/18723 | 9.87e-05 | 7.43e-04 | 55 |
GO:00018437 | Oral cavity | OSCC | neural tube closure | 52/7305 | 88/18723 | 1.06e-04 | 7.84e-04 | 52 |
GO:006082810 | Oral cavity | OSCC | regulation of canonical Wnt signaling pathway | 128/7305 | 253/18723 | 1.11e-04 | 8.16e-04 | 128 |
GO:00606066 | Oral cavity | OSCC | tube closure | 52/7305 | 89/18723 | 1.59e-04 | 1.10e-03 | 52 |
GO:006007010 | Oral cavity | OSCC | canonical Wnt signaling pathway | 148/7305 | 303/18723 | 2.89e-04 | 1.82e-03 | 148 |
GO:00018388 | Oral cavity | OSCC | embryonic epithelial tube formation | 66/7305 | 121/18723 | 3.70e-04 | 2.26e-03 | 66 |
GO:003514810 | Oral cavity | OSCC | tube formation | 78/7305 | 148/18723 | 4.82e-04 | 2.85e-03 | 78 |
GO:00163315 | Oral cavity | OSCC | morphogenesis of embryonic epithelium | 77/7305 | 147/18723 | 6.63e-04 | 3.72e-03 | 77 |
GO:00721758 | Oral cavity | OSCC | epithelial tube formation | 69/7305 | 132/18723 | 1.32e-03 | 6.56e-03 | 69 |
GO:00219158 | Oral cavity | OSCC | neural tube development | 77/7305 | 152/18723 | 2.26e-03 | 1.00e-02 | 77 |
GO:00605629 | Oral cavity | OSCC | epithelial tube morphogenesis | 149/7305 | 325/18723 | 6.73e-03 | 2.50e-02 | 149 |
GO:00487713 | Oral cavity | OSCC | tissue remodeling | 84/7305 | 175/18723 | 9.39e-03 | 3.36e-02 | 84 |
GO:00456674 | Oral cavity | OSCC | regulation of osteoblast differentiation | 65/7305 | 132/18723 | 1.06e-02 | 3.60e-02 | 65 |
GO:0051098110 | Oral cavity | LP | regulation of binding | 140/4623 | 363/18723 | 2.47e-09 | 1.10e-07 | 140 |
GO:004339319 | Oral cavity | LP | regulation of protein binding | 80/4623 | 196/18723 | 4.41e-07 | 1.23e-05 | 80 |
GO:0051099110 | Oral cavity | LP | positive regulation of binding | 67/4623 | 173/18723 | 2.86e-05 | 4.51e-04 | 67 |
GO:001605515 | Oral cavity | LP | Wnt signaling pathway | 140/4623 | 444/18723 | 5.80e-04 | 5.35e-03 | 140 |
GO:003209215 | Oral cavity | LP | positive regulation of protein binding | 35/4623 | 85/18723 | 5.94e-04 | 5.44e-03 | 35 |
GO:019873815 | Oral cavity | LP | cell-cell signaling by wnt | 140/4623 | 446/18723 | 7.12e-04 | 6.38e-03 | 140 |
GO:000184113 | Oral cavity | LP | neural tube formation | 39/4623 | 102/18723 | 1.64e-03 | 1.25e-02 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HRC | SNV | Missense_Mutation | novel | c.751G>A | p.Asp251Asn | p.D251N | P23327 | protein_coding | tolerated(0.12) | possibly_damaging(0.685) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
HRC | SNV | Missense_Mutation | novel | c.1345N>C | p.Glu449Gln | p.E449Q | P23327 | protein_coding | tolerated(0.3) | benign(0.067) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
HRC | SNV | Missense_Mutation | | c.1431N>C | p.Leu477Phe | p.L477F | P23327 | protein_coding | tolerated(0.12) | benign(0.044) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HRC | SNV | Missense_Mutation | | c.1758N>G | p.Ile586Met | p.I586M | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.854) | TCGA-AO-A1KR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
HRC | SNV | Missense_Mutation | novel | c.811N>T | p.His271Tyr | p.H271Y | P23327 | protein_coding | tolerated(0.06) | probably_damaging(0.982) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HRC | SNV | Missense_Mutation | rs766836022 | c.1951N>A | p.Glu651Lys | p.E651K | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
HRC | SNV | Missense_Mutation | novel | c.1600G>A | p.Glu534Lys | p.E534K | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.587) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
HRC | SNV | Missense_Mutation | | c.68N>A | p.Pro23His | p.P23H | P23327 | protein_coding | deleterious(0) | possibly_damaging(0.543) | TCGA-E2-A158-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | arimidex | SD |
HRC | SNV | Missense_Mutation | novel | c.704G>C | p.Gly235Ala | p.G235A | P23327 | protein_coding | tolerated(0.51) | benign(0) | TCGA-C5-A1M6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
HRC | SNV | Missense_Mutation | rs563550433 | c.872G>A | p.Arg291His | p.R291H | P23327 | protein_coding | tolerated(1) | benign(0) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |